P. Warkentin

发表

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products

J. Talmadge, J. Vose, M. Varney, 1999, Bone Marrow Transplantation.

Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome.

P. Iversen, J. Jackson, J. Sharp, 1997, Journal of hematotherapy.

Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.

P. Iversen, J. Jackson, M. Bishop, 1994, Progress in clinical and biological research.

Comparison of ISHAGE protocol CD34 cell enumeration with a lineage negative backgating technique.

J. Jackson, M. Bishop, A. Kessinger, 1999, Cytotherapy.

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

M. Bishop, J. Armitage, A. Kessinger, 1998, Bone Marrow Transplantation.

Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.

J. Jackson, S. Joshi, A. Kessinger, 2000, Cytotherapy.

Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor.

P. Bierman, J. Jackson, M. Bishop, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies.

J. Armitage, P. Bierman, J. Vose, 1995, Experimental hematology.

High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft.

J. Armitage, J. Vose, J. Jackson, 1994, Blood.

Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization.

J. Armitage, M. Tempero, M. Bishop, 1995, Journal of hematotherapy.

Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.

J. Armitage, P. Bierman, J. Vose, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia.

D. Weisenburger, J. Armitage, A. Kessinger, 1989, Bone marrow transplantation.

Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation

E. Bayever, S. Strandjord, M. Abromowitch, 1997, Bone Marrow Transplantation.

Semiclosed system for human and porcine islet isolation using the COBE 2991 cell processor with the triple-bag processing sets.

L. Weide, P. Warkentin, M. Damon-Burke, 1994, Transplantation proceedings.

Role of the blood bank in bone marrow transplantation.

J. McCullough, L. Lasky, P. Warkentin, 1984, Progress in clinical and biological research.

Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.

P. Bierman, W. Sanger, L. Klassen, 1991, Bone marrow transplantation.

Fatal eosinophilic disease following autologous bone marrow transplantation.

J. Jackson, P. Sammut, T. Gross, 1994, Bone Marrow Transplantation.

Cerebral infarction associated with protein C deficiency following allogeneic bone marrow transplantation.

K. Saving, W. Roberts, J. McConnell, 1991, Bone marrow transplantation.

Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents.

D. Weisenburger, J. Armitage, P. Bierman, 1992, Blood.